{"id":5029,"date":"2019-05-10T17:19:51","date_gmt":"2019-05-10T11:49:51","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5029"},"modified":"2024-03-21T15:58:40","modified_gmt":"2024-03-21T10:28:40","slug":"acne-vulgaris-market-outlook","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook","title":{"rendered":"Acne Vulgaris Market Outlook"},"content":{"rendered":"\n

Acne Vulgaris <\/strong>(AV) is one of the most common dermatological conditions worldwide and is a chronic skin disease\/disorder of pilosebaceous follicles. The androgens increase the production of sebum, which causes an inflammatory reaction. The disease is characterized by blockage of hair follicles and the accompanying sebaceous gland and is observed mostly in adolescence. The infection is characterized by non-inflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules. It typically affects the face, upper chest and back. Based on the extent of severity of acne, this disorder is classified as Mild, Moderate and Severe.
<\/p>\n\n\n\n

Acne Vulgaris Epidemiology<\/strong>
<\/h4>\n\n\n\n

As per DelveInsight\u2019s estimation, the United States accounted for the highest number of cases of Acne Vulgaris wit h approximately 47 million diagnosed prevalent cases in 2017. However, in the EU5, the United Kingdom showed the highest number of Diagnosed Prevalent Cases of Acne Vulgaris in 2017, whereas Spain showed the lowest number of diagnosed cases. Acne vulgaris Epidemiology<\/strong> is not limited to adolescence. In fact, twelve per cent of women and five per cent of men aged 25 years have acne vulgaris. By the age of 45 years, 5% of both men and women still have acne vulgaris.
During adolescence, acne vulgaris is more prevalent in males. In adulthood, acne vulgaris is more common in women than in men.<\/strong>
According to a study conducted by K. Bhate et. al. 2012, moderate-to-severe acne affects around 20% of young people in the UK. In the U.S. Acne Vulgaris is known to affect around 80% of Americans.
Out of these, twenty per cent have severe acne, which can result in permanent physical scarring and mental anguish.
<\/p>\n\n\n\n

Acne Vulgaris Therapies<\/strong>
<\/h4>\n\n\n\n

The Acne Vulgaris therapeutic market is designed based on a better understanding of the pathogenesis of acne. Acne Vulgaris market is segmented into topical and oral combination treatments. In topical therapy, various agents, such as benzoyl peroxide, antibiotics, topical retinoid, etc. can be used as combination medications. On the other hand, systemic therapy includes oral antibiotics, hormonal therapy, isotretinoin, and others. The advice on the therapy to be administered is based on the severity of the acne. Phototherapy and lesion removal are also found to be effective in a few cases. The current Acne Vulgaris market<\/a><\/strong> is dependent on both the marketed as well as generic products. The branded marketed drugs such as Acanya <\/strong>(Valeant Pharmaceuticals), Tazorac <\/strong>(Allergan), Veltin <\/strong>(Almirall), Duac <\/strong>(GlaxoSmithKline), Epiduo <\/strong>and Epiduo Forte <\/strong>(Galderma), BenzaClin Topical Gel <\/strong>(Dermik Laboratories a business of Sanofi-Aventis) etc., along with antimicrobial and anti-inflammatory drugs hold the major position in the acne market. On the flip side, patent expiry of the marketed drugs is also set to impact the overall market size of Acne Vulgaris. On the pipeline front, there are multiple clinical trials assessing new formulations or combinations of established acne treatments, and novel uses of antimicrobials.
<\/p>\n\n\n\n

Acne Vulgaris Therapeutic Market<\/strong>
<\/h4>\n\n\n\n

Acne Vulgaris current treatments are effective, however, regimens are complex and side effects are common. A better understanding of the pathology of acne is leading to the identification of new and safer therapeutic targets. There are many products in the final phase of the pipeline, all of which are in topical therapy area and targets various mechanisms such as IDP-120 <\/strong>(Valeant Pharmaceuticals), ASC-J9 <\/strong>(AndroScience), DRM01 <\/strong>(DRM01), BPX-01<\/strong> (BioPharmX), and AOB101 <\/strong>(AOBiome).
BPX-01,<\/strong> a novel topical gel formulation of minocycline for the treatment of inflammatory acne, is the most promising clinical compound based on the patented HyantX delivery system. In July 2018, FDA waived its requirement for a dermal carcinogenicity study for BPX-01, eliminating several years of non-clinical research normally required for FDA review, leading to the compound\u2019s acceleration towards regulatory schedule. Furthermore, it has been observed that the novel therapies in the pipeline, such as live bacterial therapy, are also gaining importance through better efficacy and safety results and less adverse events. An example of this is AOBiome<\/strong>, which has its live bacteria therapy in Phase IIb stage of clinical development. Some candidates, however, have recently failed clinical trials. Notably, Xenon\u2019s phase II small-molecule inhibitor of sebum production XEN801 <\/strong>and Novan\u2019s SB204<\/strong>, a NO-releasing topical gel, are two such candidates. Even though these candidates are more effective than placebo in phase II, however, they failed to meet one of its phase III endpoints. The biggest hurdle identified during their studies was the requirement of both objective and subjective testing in clinical trials. DelveInsight predicts that the promising key candidates in the late phase of clinical development will impact the Acne Vulgaris market during the forecast period (2018-2028).<\/p>\n\n\n\n

There are huge numbers of new treatments currently being considered for acne vulgaris, some of which target the inflammatory cascade of acne pathogenesis. With the advancements in the prognosis, diagnosis and pipeline therapies, DelveInsight estimates further evolution of the market of Acne Vulgaris.<\/p>\n","protected":false},"excerpt":{"rendered":"

Acne Vulgaris (AV) is one of the most common dermatological conditions worldwide and is a chronic skin disease\/disorder of pilosebaceous follicles. The androgens increase the production of sebum, which causes an inflammatory reaction. The disease is characterized by blockage of hair follicles and the accompanying sebaceous gland and is observed mostly in adolescence. The infection […]<\/p>\n","protected":false},"author":1,"featured_media":5030,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[3620,3903,17710,17711,3905,3904],"industry":[17225],"therapeutic_areas":[17237],"class_list":["post-5029","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-acne-vulgaris","tag-acne-vulgaris-market","tag-acne-vulgaris-pipeline","tag-acne-vulgaris-therapeutic-market","tag-acne-vulgaris-therapies","tag-acne-vulgaris-treatment","industry-pharmaceutical","therapeutic_areas-dermatology"],"acf":[],"yoast_head":"\nAcne Vulgaris Market Outlook - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Acne Vulgaris Pipeline IDP-120 (Valeant Pharmaceuticals), ASC-J9 (AndroScience), DRM01 (DRM01), BPX-01 (BioPharmX), and AOB101 (AOBiome)...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acne Vulgaris Market Outlook - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Acne Vulgaris Pipeline IDP-120 (Valeant Pharmaceuticals), ASC-J9 (AndroScience), DRM01 (DRM01), BPX-01 (BioPharmX), and AOB101 (AOBiome)...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-10T11:49:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-21T10:28:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/10173206\/ext11.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Acne Vulgaris Market Outlook - DelveInsight Business Research","description":"Acne Vulgaris Pipeline IDP-120 (Valeant Pharmaceuticals), ASC-J9 (AndroScience), DRM01 (DRM01), BPX-01 (BioPharmX), and AOB101 (AOBiome)...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook","og_locale":"en_US","og_type":"article","og_title":"Acne Vulgaris Market Outlook - DelveInsight Business Research","og_description":"Acne Vulgaris Pipeline IDP-120 (Valeant Pharmaceuticals), ASC-J9 (AndroScience), DRM01 (DRM01), BPX-01 (BioPharmX), and AOB101 (AOBiome)...","og_url":"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-10T11:49:51+00:00","article_modified_time":"2024-03-21T10:28:40+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/10173206\/ext11.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook","url":"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook","name":"Acne Vulgaris Market Outlook - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/10173206\/ext11.png","datePublished":"2019-05-10T11:49:51+00:00","dateModified":"2024-03-21T10:28:40+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Acne Vulgaris Pipeline IDP-120 (Valeant Pharmaceuticals), ASC-J9 (AndroScience), DRM01 (DRM01), BPX-01 (BioPharmX), and AOB101 (AOBiome)...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/acne-vulgaris-market-outlook#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/10173206\/ext11.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/10173206\/ext11.png","width":647,"height":345,"caption":"Acne Vulgaris"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/10173206\/ext11-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">acne vulgaris<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acne Vulgaris Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acne Vulgaris Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acne Vulgaris Therapeutic market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acne Vulgaris Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acne Vulgaris Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">acne vulgaris<\/span>","<span class=\"advgb-post-tax-term\">Acne Vulgaris Market<\/span>","<span class=\"advgb-post-tax-term\">Acne Vulgaris Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Acne Vulgaris Therapeutic market<\/span>","<span class=\"advgb-post-tax-term\">Acne Vulgaris Therapies<\/span>","<span class=\"advgb-post-tax-term\">Acne Vulgaris Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 10, 2019","modified":"Updated on Mar 21, 2024"},"absolute_dates_time":{"created":"Posted on May 10, 2019 5:19 pm","modified":"Updated on Mar 21, 2024 3:58 pm"},"featured_img_caption":"Acne Vulgaris","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5029"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5029\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5030"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5029"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5029"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}